Metabolic Health • Heart • Brain • Cancer • Longevity

What If Weight Loss Is Only the Beginning?

GLP-1 medications are usually discussed as weight-loss drugs. The more interesting question may be what happens downstream when obesity, glucose, cardiovascular risk, kidney stress, and other metabolic problems improve at the same time.

We do not yet have twenty or thirty years of randomized data for modern obesity-dose GLP-1 therapy.

But we are beginning to accumulate something potentially more important than a smaller number on the scale: actual disease-outcome data.

Drew Kirkley, MSN, APRN, AGNP-C KirkleyCare Metabolic & Personalized Wellness

For years, the conversation around GLP-1 medications sounded something like this:

How much weight did they lose?

That is an important outcome.

But it may eventually turn out to be one of the least interesting parts of the story.

Excess adiposity does not exist in isolation.

It interacts with glucose regulation, insulin resistance, blood pressure, inflammation, liver health, kidney health, sleep apnea, cardiovascular disease, mobility, and multiple cancers.

So when a therapy improves several parts of that biological environment simultaneously, it raises a much bigger question:

What diseases might become less common twenty years downstream?

Heart attacks?

Strokes?

Kidney failure?

Dementia?

Certain cancers?

We do not have definitive answers to all of those questions.

But the signals are becoming difficult to ignore.

First: “GLP-1” Is Not One Drug

Class effects should not automatically be assumed for every molecule

GLP-1 receptor agonists include medications such as semaglutide, liraglutide, and dulaglutide.

Tirzepatide is slightly different because it activates both the GIP and GLP-1 receptors.

These medications share overlapping physiology, but they are not interchangeable research compounds.

A cardiovascular outcome demonstrated with semaglutide should not automatically be assigned to every GLP-1-based medication.

Follow the Specific Evidence

Throughout this article, “GLP-1 medications” describes the broader therapeutic category, but specific outcomes should be attributed to the specific molecule and population actually studied.

Not Every Benefit Has the Same Level of Evidence

This is probably the most important distinction in the entire conversation

Established

Cardiovascular Outcomes

Randomized outcome trials demonstrate reductions in major cardiovascular events with specific GLP-1 therapies in selected high-risk populations.

Supported

Kidney Outcomes

Semaglutide has reduced clinically meaningful kidney outcomes in randomized patients with type 2 diabetes and chronic kidney disease.

Emerging

Dementia & Cancer

Large observational studies are generating intriguing signals, but they cannot establish prevention or causality.

Still Unknown

Multi-Decade Effects

We do not yet know the full benefit-risk profile of using modern obesity-dose therapy continuously across decades.

Why Would a Weight-Loss Medication Affect More Than Weight?

Because body weight is connected to an entire metabolic environment

A GLP-1 medication does not simply make a scale number smaller.

In many patients, treatment is accompanied by changes in several biological variables at the same time.

Body Fat

Lower adiposity changes the endocrine and metabolic environment created by excess fat tissue.

Glucose

GLP-1-based therapies can improve glycemic control and reduce progression toward diabetes in appropriate populations.

Blood Pressure

Weight reduction and metabolic improvement can influence cardiovascular workload and blood pressure.

Inflammation

Weight loss and improved metabolic health can reduce several inflammatory signals associated with obesity.

Kidney Stress

Specific GLP-1 therapies now have randomized evidence of kidney protection in selected high-risk patients.

Liver Health

Reducing excess adiposity and metabolic dysfunction can improve metabolic liver disease in many patients.

Mobility

Less excess body weight may reduce mechanical load and make physical activity easier for some people.

Cardiovascular Risk

This is no longer theoretical for semaglutide in certain high-risk populations.

Less Excess Adiposity

→

Better Metabolic Environment

→

Less Organ Stress

→

Fewer Downstream Events?

The Question Mark Matters

Improving a risk factor does not automatically prove that every disease associated with that risk factor will be prevented.

Ultimately, we need outcome data.

For Cardiovascular Disease, We Already Have Outcome Data

This is where the conversation moved beyond weight loss

The SELECT trial enrolled more than 17,600 adults with overweight or obesity and established cardiovascular disease—but without diabetes.

Participants received semaglutide 2.4 mg or placebo in addition to standard care.

SELECT Trial

Randomized, double-blind cardiovascular outcome trial

17,604 participants

6.5% major cardiovascular event with semaglutide

8.0% major cardiovascular event with placebo

The primary outcome—cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke—was reduced by about 20% on a relative basis.

This was meaningful enough that the FDA subsequently approved Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and overweight or obesity.

For cardiovascular disease, we are no longer asking whether the biomarkers look better.

We have fewer actual cardiovascular events.

What About Stroke Specifically?

The signal is encouraging—but individual trials need to be interpreted carefully

Stroke is part of the cardiovascular composite used in several major GLP-1 outcome trials.

In SUSTAIN-6, which enrolled patients with type 2 diabetes at high cardiovascular risk, nonfatal stroke occurred in 1.6% of semaglutide-treated patients compared with 2.7% receiving placebo.

That corresponded to a hazard ratio of 0.61.

SELECT was somewhat different.

The overall cardiovascular composite clearly improved, but the individual nonfatal-stroke result by itself was not statistically significant.

Don’t Turn a Composite Benefit Into an Unsupported Claim

Semaglutide has strong cardiovascular-outcome evidence. There is also supportive evidence for stroke reduction, particularly across high-risk diabetes studies.

But we should not tell every patient that a GLP-1 medication has been proven to prevent their future stroke.

Then the Kidney Data Arrived

Another example of benefits extending beyond weight and glucose

The FLOW trial randomized 3,533 patients with type 2 diabetes and chronic kidney disease to semaglutide or placebo.

FLOW Trial

Randomized kidney-outcome trial

24% lower relative risk of the primary kidney outcome

18% lower major cardiovascular-event risk

20% lower all-cause mortality risk

That does not mean every person taking semaglutide receives the same kidney benefit.

FLOW involved a very specific high-risk population.

But again, the important point is that we are measuring real clinical events, not simply watching the scale move.

Biomarkers Are Clues. Outcomes Are the Goal.

This distinction becomes critical when we talk about dementia and cancer

The Tempting Assumption

Weight Improves

Glucose Improves

Inflammation Improves

Risk Factors Improve

Disease Must Improve

That last step is where we can get into trouble.

A biomarker may correlate with disease risk.

It may even sit directly inside the biological pathway.

But changing a biomarker does not always change the clinical outcome we care about.

Better biology gives us a reason to investigate. It does not give us permission to skip the outcome trial.

Could GLP-1 Therapy Reduce Dementia Risk?

This may be one of the most interesting unanswered questions

Dementia does not develop overnight.

The biological processes leading toward cognitive decline may evolve over many years.

Cardiovascular disease, diabetes, hypertension, obesity, kidney disease, and metabolic dysfunction can all interact with brain health.

That makes the idea of modifying metabolic risk decades earlier biologically interesting.

Metabolic Pathway

Improving diabetes, obesity, and vascular risk could indirectly improve the environment in which the aging brain has to function.

Neurologic Interest

GLP-1 signaling has also generated research interest involving neuroinflammation, neuronal metabolism, and neurodegenerative biology.

The Missing Piece

We still need randomized prevention trials showing fewer people actually develop dementia.

The Real-World Dementia Signal Is Interesting

Association is not causation—but the size of the databases gets attention

A 2024 target-trial-emulation study examined more than one million eligible patients with type 2 diabetes without a previous Alzheimer’s diagnosis.

Semaglutide users had lower rates of first-time Alzheimer’s disease diagnosis compared with several other diabetes treatments.

Depending on the comparator, the reported hazard ratios ranged from roughly 0.33 against insulin to 0.59 compared with other GLP-1 receptor agonists.

A subsequent 2025 real-world analysis examining broader Alzheimer’s-related dementias also found lower dementia incidence among semaglutide users compared with insulin, metformin, and older GLP-1 therapies.

Very Interesting. Still Not Proof.

Electronic-health-record studies attempt to adjust for differences between groups, but they cannot eliminate every form of confounding.

People prescribed semaglutide may differ from comparison groups in ways that influence dementia risk.

Then Came an Important Reality Check

Semaglutide did not slow established Alzheimer’s disease in Phase 3

Novo Nordisk tested oral semaglutide in two large randomized Phase 3 trials known as EVOKE and EVOKE+.

Together, the studies enrolled 3,808 adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease.

After two years, semaglutide did not significantly slow clinical disease progression compared with placebo.

What makes the result particularly interesting is that Alzheimer’s-related biomarkers did improve.

The clinical outcome did not.

Biomarkers Changed

Semaglutide produced changes in Alzheimer’s-related biological markers during the trials.

Disease Progression Did Not

Those biological changes did not translate into a statistically significant slowing of clinical progression.

This may be one of the best modern examples of why biomarkers are not the same thing as outcomes.

But Prevention and Treatment Are Not the Same Question

Failure to slow established Alzheimer’s disease does not answer whether earlier metabolic treatment could change future dementia risk

This distinction matters.

Giving semaglutide to someone who already has measurable Alzheimer’s disease asks:

Can this medication slow an existing neurodegenerative process?

The Phase 3 answer so far is: not convincingly.

But using metabolic therapy years earlier asks a different question:

Could reducing obesity, diabetes, vascular disease, kidney disease, and other metabolic risks reduce the probability of dementia developing later?

We do not yet have a randomized answer to that question.

This Is a Hypothesis Worth Testing

The observational signal is intriguing. The known metabolic and cardiovascular benefits make biological sense.

But “may reduce future dementia risk” and “prevents Alzheimer’s disease” are two very different claims.

Then There Is Cancer

Another area where the early data are provocative—but not definitive

Excess adiposity is associated with increased risk for multiple cancers.

That immediately raises a reasonable question:

If a therapy produces substantial, sustained reductions in excess body fat and improves the metabolic environment around that fat, could certain obesity-associated cancers become less common?

Researchers are beginning to look.

2024

1.65 Million Patients With T2D

GLP-1 receptor agonists were associated with lower risk of 10 of 13 obesity-associated cancers compared with insulin.

2025

Adults With Obesity

A matched cohort of more than 86,000 adults found lower overall cancer incidence among GLP-1 users compared with nonusers.

2026

Obesity Without Diabetes

A target-trial-emulation study found lower short-term incidence of obesity-associated cancers among GLP-1 users compared with people receiving diet or exercise counseling alone.

The Comparator Changes the Cancer Story

This is why observational research has to be interpreted carefully

In the 2024 study of more than 1.65 million patients with type 2 diabetes, GLP-1 receptor agonists were associated with lower rates of ten obesity-associated cancers compared with insulin.

These included colorectal, endometrial, ovarian, liver, pancreatic, gallbladder, esophageal, kidney cancers, meningioma, and multiple myeloma.

That sounds dramatic.

But there is an important detail:

When GLP-1 users were compared with metformin instead of insulin, the investigators did not find statistically significant reductions in those cancers.

Comparator Matters

People who require insulin often have longer-standing or more advanced diabetes than people treated with other medications.

Observational studies can adjust for known differences, but some differences may remain.

A 2025 Obesity Cohort Added Another Signal

This study moved beyond diabetes alone

GLP-1 Use and Cancer Risk in Adults With Obesity

Retrospective matched cohort • JAMA Oncology • 2025

86,632 matched adults

0.83 hazard ratio for overall cancer incidence

17% lower relative overall cancer incidence

Lower incidence was specifically reported for endometrial cancer, ovarian cancer, and meningioma.

There was also a possible signal toward increased kidney cancer that deserves further study.

Again: association, not proof of prevention.

The 2026 Data Became Even More Interesting

Researchers specifically studied obesity without diabetes

A 2026 target-trial-emulation study evaluated obese adults without diabetes.

After matching, the analysis included more than 161,000 people.

GLP-1 use was associated with a lower short-term incidence of a composite of 13 obesity-associated cancers compared with diet or exercise counseling.

2026 Annals of Oncology Analysis

Obesity without diabetes • Median follow-up approximately 2 years

161,798 propensity-matched participants

0.59 hazard ratio for obesity-associated cancer composite

~2 Years median follow-up

Two Years Is Not Long-Term Cancer Prevention

Many cancers develop over years or decades.

The study itself was designed to evaluate short-term cancer incidence, not prove lifelong cancer prevention.

If Cancer Risk Eventually Falls, Why Might That Happen?

We should not automatically assume the medication is directly “anti-cancer”

There are several possibilities.

Some could be indirect.

Substantial fat loss changes the metabolic environment.

Insulin signaling can improve.

Glucose exposure may improve.

Liver fat may improve.

Chronic inflammatory signaling associated with obesity may change.

Physical activity may become easier.

Those effects could theoretically influence cancer risk without the medication directly killing a single cancer cell.

Sometimes preventing disease may be less about attacking the disease and more about changing the environment in which the disease develops.

We Also Have to Discuss the Cancer Warning

The cancer conversation cannot include only the reassuring data

Semaglutide products carry an FDA boxed warning regarding thyroid C-cell tumors.

In rodent studies, semaglutide caused thyroid C-cell tumors.

Whether that finding translates to humans remains unknown.

For that reason, Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Reassuring Signal

Large human observational datasets have not produced a simple signal showing broad increases in overall cancer incidence.

Remaining Uncertainty

Multi-decade cancer surveillance is still unavailable for modern high-dose obesity treatment.

“May Reduce Some Cancers” Does Not Mean “No Cancer Risk”

Benefits and risks need to be evaluated separately rather than turning either side into a blanket conclusion.

What Do We Mean When We Say “We Don’t Know the Long-Term Effects”?

Long-term is relative

GLP-1 biology is not brand new.

Earlier GLP-1 receptor agonists have been used clinically for years, and semaglutide was first approved in the United States in 2017.

What we do not have is a randomized trial showing what happens when millions of relatively young adults use high-potency obesity therapy continuously for twenty or thirty years.

Months GI tolerance, appetite, weight response

Years Cardiovascular and kidney outcome data

Decades Dementia, cancer, lifelong body composition

Lifetime Full benefit-risk balance still unknown

Unknown Does Not Mean Unsafe

It means the observation period has not yet been long enough to answer every question.

The same uncertainty also applies to potential benefits that may require decades to become visible.

The Long Game Still Has Tradeoffs

Better metabolic health does not make a medication biologically free

Gastrointestinal Effects

Nausea, vomiting, diarrhea, constipation, and intolerance can limit therapy in some people.

Gallbladder Disease

Gallstone and gallbladder risks are part of the established safety discussion.

Pancreatitis

Acute pancreatitis remains an important labeled clinical warning.

Lean Tissue

Significant weight loss can include lean-mass loss, making protein intake and resistance training important considerations.

Nutrition

Profound appetite suppression can make inadequate protein, calories, or micronutrient intake easier to overlook.

Retinopathy

Rapid glycemic improvement deserves consideration in patients with diabetes and preexisting retinopathy.

Thyroid Warning

Rodent C-cell tumor findings remain part of FDA labeling even though their relevance to humans is uncertain.

Long-Term Unknowns

Multi-decade exposure data for modern obesity treatment simply do not exist yet.

But “We Don’t Have 30-Year Data” Cuts Both Ways

Doing nothing also has long-term consequences

This is a part of the risk conversation that is often forgotten.

Imagine someone is 45 years old with obesity, hypertension, insulin resistance, sleep apnea, fatty liver, and rising glucose.

We could say:

“We don’t know what thirty years of GLP-1 therapy will do.”

True.

But we should immediately ask the other question:

What are thirty more years of obesity, hypertension, insulin resistance, sleep apnea, and metabolic dysfunction likely to do?

The decision is rarely medication versus zero risk. It is one risk profile versus another.

Maybe We Should Stop Thinking of These as “Weight-Loss Drugs”

Weight loss may be one visible expression of a much larger metabolic intervention

If someone loses 20% of their body weight but we only celebrate the number on the scale, we may be missing the real victory.

What happened to their blood pressure?

Their glucose?

Their liver?

Their kidneys?

Their cardiovascular risk?

Their sleep apnea?

Their mobility?

Their ability to exercise?

Their risk profile twenty years from now?

Health Is a Systems Outcome

The most meaningful effect of a metabolic medication may not be the first biomarker that changes.

It may be the disease that never develops.

We Should Be Excited Without Getting Ahead of the Science

There is plenty here to be optimistic about without pretending the unanswered questions are settled

Too Far

“GLP-1 medications prevent Alzheimer’s disease and cancer.”

We do not have evidence strong enough to make that statement.

Scientifically Defensible

“GLP-1 therapies improve several established disease risk factors, have proven cardiovascular and kidney benefits in selected populations, and are generating emerging signals for reduced dementia and cancer incidence that deserve further study.”

This Could Be a Much Bigger Public-Health Story Than Weight Loss

The real payoff may happen years after the scale stops moving

Imagine millions of people entering middle age with:

Less visceral fat.

Better glucose control.

Lower cardiovascular risk.

Less kidney disease.

Better mobility.

Improved sleep apnea.

More ability to exercise.

Better metabolic health.

It would be surprising if none of those changes influenced the diseases that appear decades later.

The magnitude of that influence remains unknown.

But that may ultimately be the most important research question surrounding this class of medications.

What If the Scale Is Only the First Biomarker?

The visible effect of GLP-1 therapy is weight loss. The more important effect may eventually be a different metabolic environment maintained over years—and fewer cardiovascular, renal, neurologic, and possibly oncologic events downstream.

Weight loss is the beginning of the question. Healthspan is the outcome we actually care about.

The Right Question Is Not “Are GLP-1s Good or Bad?”

That’s too simple for a therapy affecting this many biological systems

The better questions are:

Who benefits?

What risks does that person already have?

What risks does the medication introduce?

What risks does improving obesity and metabolic health remove?

How much muscle are we preserving?

Are nutrition and resistance training part of the strategy?

What happens after five years?

Ten?

Twenty?

The most important benefit of a medication may be the event that never happens.

We already know that fewer cardiovascular events can happen in the right patients.

We already know kidney outcomes can improve in the right population.

We have intriguing—but still unproven—signals involving dementia and cancer.

And we have decades of questions still left to answer.

Follow the Outcomes, Not Just the Scale

Weight matters. But cardiovascular disease, kidney failure, stroke, dementia, cancer, mobility, strength, and independence matter more.

The ultimate goal isn’t weight loss. It’s better health for more years.

Is Metabolic Therapy the Right Lever for You?

A personalized wellness consultation can look at your goals, body composition, metabolic health, cardiovascular risk, medications, nutrition, muscle preservation, and the available options to determine what makes sense for your individual situation.

Book a Wellness Consultation

About the Author

Better health happens when the whole system works together

Drew Kirkley, MSN, APRN, AGNP-C

Adult-Gerontology Nurse Practitioner • University Nursing Professor • Founder of KirkleyCare

Drew Kirkley’s approach to personalized wellness focuses on helping people understand how metabolic health, muscle, cardiovascular risk, sleep, nutrition, hormones, medications, and other biological systems interact—and identifying practical, evidence-informed levers that may help them achieve their individual health goals.

Selected Scientific References

Randomized trials, regulatory information, and emerging observational research discussed in this article

Lincoff AM, et al. New England Journal of Medicine. 2023.
SELECT randomized trial of semaglutide and cardiovascular outcomes in adults with overweight or obesity, established cardiovascular disease, and no diabetes.
View SELECT on PubMed →

U.S. Food & Drug Administration. 2024.
FDA approval of Wegovy to reduce cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and overweight or obesity.
View FDA Announcement →

Marso SP, et al. New England Journal of Medicine. 2016.
SUSTAIN-6 cardiovascular outcome trial in patients with type 2 diabetes at high cardiovascular risk, including nonfatal stroke outcomes.
View SUSTAIN-6 →

Perkovic V, et al. New England Journal of Medicine. 2024.
FLOW randomized trial examining semaglutide and major kidney, cardiovascular, and mortality outcomes in type 2 diabetes with chronic kidney disease.
View FLOW →

Wang W, et al. Alzheimer’s & Dementia. 2024.
Target-trial-emulation study examining associations between semaglutide use and first-time Alzheimer’s disease diagnosis in patients with type 2 diabetes.
View Study →

Wang W, et al. Journal of Alzheimer’s Disease. 2025.
Large real-world target-trial-emulation study examining semaglutide and Alzheimer’s disease-related dementias.
View Study →

Novo Nordisk. EVOKE / EVOKE+ Phase 3 Results. 2025.
Two randomized Phase 3 studies found that oral semaglutide did not significantly slow clinical progression in early symptomatic Alzheimer’s disease despite changes in Alzheimer’s-related biomarkers.
View Phase 3 Results →

Wang L, et al. JAMA Network Open. 2024.
Cohort of more than 1.65 million patients with type 2 diabetes examining GLP-1 receptor agonists and 13 obesity-associated cancers.
View Study →

Dai H, et al. JAMA Oncology. 2025.
Retrospective matched cohort examining GLP-1 receptor agonist use and cancer incidence among adults with overweight or obesity.
View Study →

Hsu AHC, et al. Annals of Oncology. 2026.
Target-trial-emulation analysis examining GLP-1 receptor agonist use and short-term obesity-associated cancer incidence among obese adults without diabetes.
View Study →

Current Wegovy Prescribing Information.
Current FDA-approved labeling, including cardiovascular indication, warnings, precautions, and boxed warning regarding thyroid C-cell tumors.
View Current Label →

Educational Disclaimer: This article is intended for general education and commentary and does not provide individualized medical advice. Cardiovascular and kidney benefits described above apply to specific medications and patient populations studied in randomized clinical trials and should not automatically be generalized to every GLP-1-based therapy or patient. Current evidence does not establish GLP-1 receptor agonists as medications for the prevention of Alzheimer’s disease or cancer. Dementia and cancer findings discussed above are primarily observational and may be affected by residual confounding. Semaglutide did not significantly slow clinical progression in the EVOKE and EVOKE+ Phase 3 trials involving patients with early symptomatic Alzheimer’s disease. GLP-1 medications also have established adverse effects, contraindications, and unanswered long-term questions. Medication decisions should be individualized according to medical history, expected benefit, potential risk, body composition, nutritional status, concurrent medications, and patient goals.